SCHEMBL2114643

SCHEMBL2114643

[O]CCCN1CCCCC1CF

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 3/20 0.39
S1PR3 Q99500 3/20 0.39
S1PR5 Q9H228 3/20 0.39
S1PR4 O95977 1/20 0.35
HSD17B10 Q99714 1/20 0.33
LTA4H P09960 2/20 0.33
HRH3 Q9Y5N1 1/20 0.33
ADRA1D P25100 3/20 0.32
ADRA1A P35348 3/20 0.32
ADRA1B P35368 3/20 0.32
OPRD1 P41143 1/20 0.31
CYP1A2 P05177 1/20 0.31
CHRM2 P08172 1/20 0.30
CHRM1 P11229 1/20 0.30
CYP3A4 P08684 1/20 0.30
CYP2D6 P10635 1/20 0.30
KCNH2 Q12809 1/20 0.30
POLB P06746 1/20 0.30
TSHR P16473 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2116271 0.87 S1PR1 (0.44) S1PR1S1PR3S1PR5S1PR4HSD17B10
SCHEMBL2114644 0.81 S1PR1 (0.39) S1PR1S1PR3S1PR5S1PR4HSD17B10
SCHEMBL2115782 0.81 S1PR1 (0.44) S1PR1S1PR3S1PR5S1PR4LTA4H
SCHEMBL2118729 0.81 HSD17B10 (0.47) S1PR1S1PR3S1PR5S1PR4HSD17B10
SCHEMBL3431905 0.79 S1PR1 (0.47) S1PR1S1PR3S1PR5S1PR4HSD17B10
SCHEMBL3424378 0.79 S1PR1 (0.47) S1PR1S1PR3S1PR5S1PR4HSD17B10
SCHEMBL3430850 0.79 S1PR1 (0.47) S1PR1S1PR3S1PR5S1PR4HSD17B10
SCHEMBL25435870 0.76 CYP1A2 (0.32) HRH3CYP1A2
SCHEMBL2116369 0.76 S1PR1 (0.45) S1PR1S1PR3S1PR5S1PR4HSD17B10
SCHEMBL3429333 0.76 SPHK1 (0.47) S1PR1S1PR3S1PR5S1PR4HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8158652-B2 1-Difluoromethyl-5-{4-[3-(1-piperidinyl)propoxy]phenyl}-2(1H)-pyridone; compounds act as histamine-H3 receptor antagonistic substances or inverse-agonistic substances; useful as preventives or remedies for various circular system diseases, nervous system diseases, metabolic system diseases MSD K.K. (JP) 2012-04-17 US disclosed
US-20080269287-A1 Substituted Pyridone Derivative MSD K.K. (JP) 2008-10-30 US disclosed
EP-1820797-A1 SUBSTITUTED PYRIDONE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269287-A1 Substituted Pyridone Derivative HRH3, HRH4, HRH1 S1PR1 476/4885S1PR3 567/4885S1PR5 912/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.